BridgeBio Pharma Inc (BBIO)
25.61
+0.13
(+0.51%)
USD |
NASDAQ |
Nov 04, 13:01
BridgeBio Pharma Revenue (Quarterly): 2.168M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.168M |
| March 31, 2024 | 211.12M |
| December 31, 2023 | 1.745M |
| September 30, 2023 | 4.091M |
| June 30, 2023 | 1.641M |
| March 31, 2023 | 1.826M |
| December 31, 2022 | 1.87M |
| September 30, 2022 | 0.338M |
| June 30, 2022 | 73.75M |
| March 31, 2022 | 1.694M |
| Date | Value |
|---|---|
| December 31, 2021 | 12.89M |
| September 30, 2021 | 2.344M |
| June 30, 2021 | 54.02M |
| March 31, 2021 | 0.462M |
| December 31, 2020 | 0.122M |
| September 30, 2020 | 8.127M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 13.82M |
| September 30, 2019 | 26.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.122M
Minimum
Dec 2020
211.12M
Maximum
Mar 2024
23.06M
Average
2.168M
Median
Jun 2024
Revenue (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 500.92M |
| Pfizer Inc | 17.70B |
| Vertex Pharmaceuticals Inc | 2.646B |
| PTC Therapeutics Inc | 186.70M |
| Bristol-Myers Squibb Co | 11.89B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -73.46M |
| Total Expenses (Quarterly) | 174.82M |
| EPS Diluted (Quarterly) | -0.39 |
| Enterprise Value | 6.072B |
| Gross Profit Margin (Quarterly) | 72.42% |
| Profit Margin (Quarterly) | -3.39K% |
| Earnings Yield | -10.27% |
| Normalized Earnings Yield | -12.49 |